ALMDT Median Technologies

Median Technologies: Liquidity Contract Transfer to Louis Capital Markets

Regulatory News:

Median Technologies (Paris:ALMDT) is announcing that on March 30, 2020, it concluded a new liquidity contract with the Company Louis Capital Markets in accordance with the Amafi charter. The contract will take effect on the morning of May 4, 2020.

This liquidity contract was concluded in accordance with the decision of the Autorité des Marchés Financiers No. 2018-01 of July 2, 2018, applicable since January 1, 2019, establishing liquidity contracts on equity securities as a permitted market practice1.

The End of the Liquidity Contract with AUREL BGC

The companies Median Technologies and AUREL BGC terminated the liquidity contract that was concluded on May 4, 2011. This termination took effect on April 30, 2020 in the evening.

On this date of April 30, 2020 in the evening, the following means appeared in the liquidity account:

  • 4,404 shares,
  • €173,829.64 in cash.

It should be recalled that as of December 31, 2019, the following resources appeared in the liquidity account:

  • 22,458 shares,
  • €141,002.52 in cash.

Regarding the implementation of the new contract concluded with LOUIS CAPITAL MARKETS, the following resources have been allocated to the liquidity account:

  • 4,404 shares transferred from the old liquidity contract,
  • €173,829.64 in cash from the old liquidity contract.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on the Euronext Growth market. ISIN: FR0011049824– ticker: ALMDT. Median is eligible for the French “PEA-PME” investment scheme. For more information: *

______________________

1
The situations or conditions leading to the suspension or termination of the liquidity contract, mentioned in the liquidity contract, are as follows:

Suspension of the contract: - Under the conditions referred to in article 5 of the afore-mentioned AMF decision. Termination of the contract: - At the end of the first 6 months of the first year, the Contract can be terminated at any time by the Issuer, with a 15 day notice under the conditions for closing the liquidity account provided for in the liquidity contract .- By the Animator, with a 15 day notice. - The contract is automatically terminated when the parties cannot, in the situation provided for in article 3.4 (balance of the liquidity account), agree on the action to be taken on the Contract. - By the Facilitator when the Liquidity Provider contract which binds the Moderator to Euronext Paris is terminated.

EN
04/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Median Technologies

Maria Vara
  • Maria Vara

Median Technologies: eyonis LCS heads for FDA nod in Q3 2025

This morning, Median announced that it has submitted a 510(k) FDA filing for eyonis LCS, remaining on track with prior guidance and with a plausible clearance expected in Q3 2025. We are confident in a positive outcome, as the submission is underpinned by two pivotal studies—REALITY and RELIVE—whic

Maria Vara
  • Maria Vara

Median Technologies: FY24 wrap-up signals cost discipline, outlook rei...

Median Technologies released its audited FY 2024 results, which contain no surprises versus the unaudited data already disclosed in prior updates (see Q4 2024 and Q1 2025 notes). Revenue for the year came in at EUR22.9m (+3.3% YoY), fully driven by iCRO services, and the order backlog stood at EUR7

Maria Vara
  • Maria Vara

Median Technologies: eyonis on track, backlog at record high

Median Technologies started 2025 with a continued positive momentum on iCRO revenues, which grew 11% YoY to EUR6m, backed by a record EUR74.8m order backlog (+5.4% QoQ) driven by new wins from a Top 3 pharma client. Q1 was a pivotal quarter on the clinical side, with the pivotal RELIVE study for ey

Maria Vara
  • Maria Vara

Median technologies: Full RELIVE results cement eyonis case, to launch...

Yesterday post-market, Median Technologies released the full results from its pivotal RELIVE study, confirming that eyonis LCS, its AI-powered SaMD for lung cancer screening, met all secondary endpoints in addition to the previously announced primary endpoint (p = 0.027). The final data reinforces

 PRESS RELEASE

Median Technologies répond aux conditions d’éligibilité du dispositif ...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT) confirme aujourd’hui son éligibilité au dispositif PEA-PME conformément aux dispositions des articles L. 221-32-2 et D. 221-113-5 et suivant du Code monétaire et financier précisant les conditions d'appréciation des critères d'éligibilité, à savoir : Moins de 5 000 salariés, Un chiffre d'affaires annuel inférieur à 1,5 milliard d'euros ou un total de bilan inférieur à 2 milliards d'euros. Les actions Median Technologies continuent en conséquence d'être intégrées au sein des comptes PEA...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch